疾病
生物
老年斑
临床试验
阿尔茨海默病
神经科学
病态的
淀粉样蛋白(真菌学)
阿尔茨海默病的生物化学
生物信息学
病理
淀粉样前体蛋白
医学
植物
作者
Justin M. Long,David M. Holtzman
出处
期刊:Cell
[Elsevier]
日期:2019-09-26
卷期号:179 (2): 312-339
被引量:2128
标识
DOI:10.1016/j.cell.2019.09.001
摘要
Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiology. The presence of extracellular β-amyloid deposition as neuritic plaques and intracellular accumulation of hyperphosphorylated tau as neurofibrillary tangles remains the primary neuropathologic criteria for AD diagnosis. However, a number of recent fundamental discoveries highlight important pathological roles for other critical cellular and molecular processes. Despite this, no disease-modifying treatment currently exists, and numerous phase 3 clinical trials have failed to demonstrate benefits. Here, we review recent advances in our understanding of AD pathobiology and discuss current treatment strategies, highlighting recent clinical trials and opportunities for developing future disease-modifying therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI